Glenview Trust’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $91.6M | Buy |
421,257
+5,930
| +1% | +$1.32M | 1.44% | 18 |
|
|
2025
Q4 | $94.9M | Buy |
415,327
+1,178
| +0.3% | +$268K | 1.46% | 19 |
|
|
2025
Q3 | $95.9M | Sell |
414,149
-7,330
| -2% | -$1.49M | 1.52% | 18 |
|
|
2025
Q2 | $78.2M | Buy |
421,479
+8,370
| +2% | +$1.56M | 1.35% | 19 |
|
|
2025
Q1 | $86.6M | Buy |
413,109
+1,974
| +0.5% | +$384K | 1.68% | 16 |
|
|
2024
Q4 | $73.1M | Buy |
411,135
+1,314
| +0.3% | +$242K | 1.37% | 19 |
|
|
2024
Q3 | $80.9M | Buy |
409,821
+2,678
| +0.7% | +$500K | 1.56% | 17 |
|
|
2024
Q2 | $69.8M | Buy |
407,143
+2,557
| +0.6% | +$424K | 1.41% | 18 |
|
|
2024
Q1 | $73.7M | Buy |
404,586
+12,772
| +3% | +$2.2M | 1.58% | 15 |
|
|
2023
Q4 | $60.7M | Buy |
391,814
+14,860
| +4% | +$2.17M | 1.49% | 17 |
|
|
2023
Q3 | $56.2M | Buy |
376,954
+15,157
| +4% | +$2.23M | 1.55% | 15 |
|
|
2023
Q2 | $48.7M | Buy |
361,797
+4,759
| +1% | +$698K | 1.33% | 17 |
|
|
2023
Q1 | $56.9M | Buy |
357,038
+3,336
| +0.9% | +$510K | 1.7% | 12 |
|
|
2022
Q4 | $57.2M | Buy |
353,702
+7,279
| +2% | +$1.12M | 1.89% | 8 |
|
|
2022
Q3 | $46.5M | Buy |
346,423
+5,712
| +2% | +$820K | 1.76% | 9 |
|
|
2022
Q2 | $52.2M | Buy |
340,711
+5,042
| +2% | +$770K | 1.92% | 8 |
|
|
2022
Q1 | $54.4M | Buy |
335,669
+23,802
| +8% | +$3.46M | 1.77% | 8 |
|
|
2021
Q4 | $42.2M | Sell |
311,867
-6,523
| -2% | -$771K | 1.4% | 15 |
|
|
2021
Q3 | $34.3M | Buy |
318,390
+13,350
| +4% | +$1.53M | 1.33% | 15 |
|
|
2021
Q2 | $34.4M | Buy |
305,040
+116,370
| +62% | +$13.1M | 1.33% | 16 |
|
|
2021
Q1 | $20.4M | Buy |
188,670
+2,621
| +1% | +$280K | 0.88% | 36 |
|
|
2020
Q4 | $19.9M | Buy |
186,049
+162
| +0.1% | +$15.6K | 0.93% | 33 |
|
|
2020
Q3 | $16.3M | Sell |
185,887
-1,604
| -0.9% | -$151K | 0.84% | 36 |
|
|
2020
Q2 | $18.4M | Buy |
187,491
+563
| +0.3% | +$49.6K | 1.05% | 28 |
|
|
2020
Q1 | $14.2M | Sell |
186,928
-4,446
| -2% | -$379K | 0.99% | 30 |
|
|
2019
Q4 | $16.9M | Buy |
191,374
+5,111
| +3% | +$424K | 0.95% | 33 |
|
|
2019
Q3 | $14.1M | Sell |
186,263
-1,635
| -0.9% | -$112K | 0.85% | 36 |
|
|
2019
Q2 | $13.7M | Sell |
187,898
-7,366
| -4% | -$579K | 0.85% | 35 |
|
|
2019
Q1 | $15.7M | Sell |
195,264
-10,059
| -5% | -$823K | 1.01% | 27 |
|
|
2018
Q4 | $18.9M | Buy |
205,323
+411
| +0.2% | +$36.1K | 1.4% | 19 |
|
|
2018
Q3 | $19.4M | Sell |
204,912
-2,519
| -1% | -$239K | 1.22% | 23 |
|
|
2018
Q2 | $19.2M | Sell |
207,431
-5,125
| -2% | -$501K | 1.43% | 18 |
|
|
2018
Q1 | $20.1M | Sell |
212,556
-3,912
| -2% | -$430K | 1.39% | 19 |
|
|
2017
Q4 | $20.9M | Sell |
216,468
-2,846
| -1% | -$268K | 1.44% | 18 |
|
|
2017
Q3 | $19.5M | Sell |
219,314
-8,653
| -4% | -$659K | 1.43% | 17 |
|
|
2017
Q2 | $16.5M | Sell |
227,967
-4,774
| -2% | -$321K | 1.28% | 21 |
|
|
2017
Q1 | $15.2M | Sell |
232,741
-18,874
| -8% | -$1.19M | 1.2% | 23 |
|
|
2016
Q4 | $15.8M | Buy |
+251,615
| New | +$15.4M | 1.31% | 19 |
|
|
2015
Q4 | $16.7M | Buy |
+281,873
| New | +$16.2M | 1.73% | 13 |
|
|
2014
Q4 | $21.6M | Buy |
+329,989
| New | +$20.8M | 2.3% | 4 |
|
|
2013
Q4 | $19M | Buy |
+359,753
| New | +$17.7M | 2.19% | 7 |
|
Other funds holding ABBV
VCM
VPM
Glenview Trust's ABBV Position: Q1 2026 in Review
Glenview Trust increased its AbbVie (ABBV) stake by 1.4% in Q1 2026, buying an estimated $1.32M and bringing the position to 421,257 shares worth $91.6M. The position accounts for 1.44% of the portfolio, ranked #18.
Glenview Trust first reported a position in ABBV in Q4 2013 and has held it in 41 quarters since. The position peaked at $95.9M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Glenview Trust held 421,257 shares of AbbVie worth $91.6M as of Q1 2026.
- Glenview Trust bought 5,930 AbbVie shares in Q1 2026, an estimated $1.32M.
- AbbVie made up 1.44% of Glenview Trust's portfolio in Q1 2026, its #18 holding.
- Glenview Trust first reported a position in AbbVie in Q4 2013 and has held it in 41 quarters since.
- Glenview Trust's AbbVie position peaked at $95.9M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.